InCarda Therapeutics raises over $5M


What does InCarda Therapeutics do?

InCarda Therapeutics, formerly known as Pleiades Cardio-Therapeutics is a privately held biotechnology company which focuses on developing and commercializing therapies for acute cardiovascular condition through inhalation route. It develops transformative therapies for patients for use in the initial moments of symptoms experiences in acute cardiovascular conditions. InCarda Therapeutics develops an inhales therapy for treating Paroxysmal atrial fibrillation- PAF.

How much InCarda Therapeutics was funded?

InCarda Therapeutics raised over $5M on April 28th , 2015 in Series A funding led by the investors Morningside Venture with the participation of other investors who include a consortium of physicians and other health care and high tech experts.

Previous funding

  • $310k in Debt Financing on October 17th, 2012.
  • $567k in  Venture round on December 19th, 2014

What is next for InCarda Therapeutics?

InCarda Therapeutics strongly believes that concept of inhaled cardiotherapeutics can change the way some acute cardiovascular conditions are treated today, by providing patients with much better therapeutic options and causing a significant saving in the health care system. As a part of the investment Reenie McCarthy of Morningside Ventures will be joining InCarda Therapeutics board of directors.

The funding raised will be used to enhance the startup’s cardiovascular program  through inhaled therapy  for treating PAF. It will also help the company advance its development of lead product to its next milestone which is a clinical proof Australia based concept trial and to advance other product concepts.

 

More about InCarda Therapeutics

InCarda Therapeutics was founded in 2009 by Gregory M. Marcus, John S. Patton, Carlos A. Schuler and Narsi Rangachari. It has its headquarters in Palo Alto, CA. This product focused cardiovascular company with experience in drug development is transforming Cardiovascular disease with pulmonary delivery. It is improving the quality of care for patients with acute cardiac conditions by developing transformative therapies.